SCHEMBL21641735

SCHEMBL21641735

CC1CN(Nc2ccccc2)CCN1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.40
ADRA2A P08913 6/20 0.37
ADRA2C P18825 6/20 0.37
ADRA2B P18089 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA7 P36544 1/20 0.36
CHRNA4 P43681 1/20 0.36
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
KCNH2 Q12809 2/20 0.34
HRH3 Q9Y5N1 2/20 0.34
HTR1A P08908 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21641749 0.81 SMN1; SMN2 (0.36) SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL18040070 0.80 SIGMAR1 (0.38) SMN1; SMN2ALDH1A1SIGMAR1TDP1
SCHEMBL4055295 0.74 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1MEN1GAAMAPT
SCHEMBL1399548 0.74 SMN1; SMN2 (0.56) CHRM1ADRA2ASMN1; SMN2KDM4EGAA
SCHEMBL18040068 0.72 ATM (0.37) SMN1; SMN2ALDH1A1GAAMAPTSIGMAR1
SCHEMBL30885149 0.71 ACHE (0.47) ALDH1A1MEN1GAARAB9AKMT2A
SCHEMBL6859733 0.70 TDP1 (0.39) ALDH1A1SIGMAR1TDP1
SCHEMBL30997628 0.69 HRH3 (0.41) SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL12662987 0.69 ESR1 (0.52) ADRA2AADRA2CADRA2BCHRNA7KCNH2
SCHEMBL3567530 0.69 ESR1 (0.52) ADRA2AADRA2CADRA2BCHRNA7KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108623615-B Macrocyclic derivatives of pyrazolo [3,4-d ] pyrimidin-3-one, pharmaceutical compositions and uses thereof 上海迪诺医药科技有限公司 2022-12-13 CN disclosed
EP-3604306-B1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2022-10-26 EP disclosed
US-11248006-B2 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2022-02-15 US disclosed
US-20200377520-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2020-12-03 US disclosed
EP-3604306-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai de Novo Pharmatech Co., Ltd. (CN) 2020-02-05 EP disclosed
CN-108623615-A The macrocyclic derivatives, its pharmaceutical composition and application of pyrazoles [3,4-d] pyrimidine -3- ketone 上海迪诺医药科技有限公司 2018-10-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377520-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF WEE1, WEE2, PDPK1 CHRM1 4840/4885ADRA2A 4304/4885ADRA2C 3434/4885
US-11248006-B2 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof WEE1, WEE2, PDPK1 CHRM1 4840/4885ADRA2A 4304/4885ADRA2C 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.